Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05547165 · ClinicalTrials.gov registry record · NA

Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

A NA study of Ductus Arteriosus, Patent, sponsored by Nationwide Children's Hospital.

Recruiting
Registry status
NA
Development phase
240
Enrollment target
20
Study locations

NCT05547165 is a NA study of Ductus Arteriosus, Patent that is actively recruiting participants, run by Nationwide Children's Hospital. The registered enrollment target is 240 participants. The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05547165, a NA study of Ductus Arteriosus, Patent, is actively recruiting participants, sponsored by Nationwide Children's Hospital.

RECRUITING
Registry status
NA
Development phase
240 participants
Enrollment target
20
Study locations

Study Summary

Patent Ductus Arteriosus is a developmental condition commonly observed among preterm infants. It is a condition where the opening between the two major blood vessels leading from the heart fail to close after birth. In the womb, the opening (ductus arteriosus) is the normal part of the circulatory system of the baby, but is expected to close at full term birth. If the opening is tiny, the condition can be self-limiting. If not, medications/surgery are options for treatment. There are two ways to treat patent ductus arteriosus - one is through closure of the opening with an FDA approved device called PICCOLO, the other is through supportive management (medications). No randomized controlled trials have been done previously to see if one of better than the other. Through our PIVOTAL study, the investigators aim to determine is one is indeed better than the other - if it is found that the percutaneous closure with PICCOLO is better, then it would immediately lead to a new standard of care. If not, then the investigators avoid an invasive costly procedure going forward.

Conditions Studied

Interventions

  • DEVICE Percutaneous Patent Ductus Arteriosus Closure (PPC)
  • COMBINATION_PRODUCT Responsive Management Intervention
  • DIAGNOSTIC_TEST Echocardiogram, cardiac

Study Locations (20)

California

  • Children's Hospital Los Angeles - Los Angeles
  • Cedars-Sinai Medical Center - Los Angeles
  • Lucille Packard Children's Hospital at Stanford - Palo Alto
  • UC Davis Children's Hospital - Sacramento

Florida

  • Joe DiMaggio Children's Hospital - Hollywood
  • Orlando Health - Orlando

Tennessee

  • Le Bonheur Children's Medical Center - Memphis
  • Monroe Carell Jr. Children's Hospital at Vanderbilt - Nashville

Alabama

  • University of Alabama - Birmingham

Arkansas

  • Arkansas Children's Hospital - Little Rock

Colorado

  • Children's Hospital Colorado - Aurora

Illinois

  • Ann and Robert H. Lurie Children's Hospital - Chicago

Massachusetts

  • Boston Children's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2023-02-21
Est. Completion 2026-02-28
Phase NA

Sponsor

Nationwide Children's Hospital

188 total trials

What the Registry Record Tells You About NCT05547165

The ClinicalTrials.gov registry entry for NCT05547165 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ductus Arteriosus, Patent appearing as the primary indexed condition, and to 3 interventions - of which Percutaneous Patent Ductus Arteriosus Closure (PPC) is the first listed.

NCT05547165 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Tennessee.

Frequently Asked Questions

What is clinical trial NCT05547165 about?

NCT05547165 is a clinical study titled "Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants". Patent Ductus Arteriosus is a developmental condition commonly observed among preterm infants. It is a condition where the opening between the two major blood vessels leading from the heart fail to close after birth. In the womb, the opening (ductus arteriosus) is the normal part of the circulatory ...

What is the current status of trial NCT05547165?

This trial is currently recruiting. It is a NA study. The enrollment target is 240 participants. The study started on 2023-02-21. Estimated completion is 2026-02-28.

What conditions does trial NCT05547165 study?

This clinical trial studies the following conditions: Ductus Arteriosus, Patent.

What interventions are being tested in trial NCT05547165?

The interventions under investigation include: Percutaneous Patent Ductus Arteriosus Closure (PPC) (DEVICE), Responsive Management Intervention (COMBINATION_PRODUCT), Echocardiogram, cardiac (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05547165?

This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05547165 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.